Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
193.46
+11.01 (6.03%)
Aug 4, 2026, 4:00 PM EDT - Market closed
Revolution Medicines Employees
Revolution Medicines had 883 employees as of December 31, 2025. The number of employees increased by 349 or 65.36% compared to the previous year.
Employees
883
Change (1Y)
349
Growth (1Y)
65.36%
Revenue / Employee
n/a
Profits / Employee
-$1,553,455
Market Cap
41.13B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 883 | 349 | 65.36% |
| Dec 31, 2024 | 534 | 156 | 41.27% |
| Dec 31, 2023 | 378 | 132 | 53.66% |
| Dec 31, 2022 | 246 | 58 | 30.85% |
| Dec 31, 2021 | 188 | 63 | 50.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 3,088 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
RVMD News
- 6 days ago - Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026 - GlobeNewsWire
- 13 days ago - Revolution Medicines' New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer - GlobeNewsWire
- 4 weeks ago - European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process - GlobeNewsWire
- 4 weeks ago - EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill - Reuters
- 4 weeks ago - Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 - GlobeNewsWire
- 5 weeks ago - Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 - GlobeNewsWire
- 6 weeks ago - Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D. - GlobeNewsWire
- 2 months ago - Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's - Reuters